|
|
Our customers say:
Lena, USA, 7/7/2010
Thank you for your service.
Just got my medicine!
I will do business with you again.
Joyce, UK, 6/23/2010
Thank you very much for your service.
I received the goods within 9 days!
Once again thank you
Zane, Latvia, 6/16/2010
Today finally got my order, so it is all ok.
I am very contented with your services, thank you.
Michael, USA, 4/11/2010
My order arrived in the mail today.
Thank you for your great service!
I will definitely bring you more business in the future!
Michael, USA, 4/11/2010
My order arrived in the mail today.
Thank you for your great service!
I will definitely bring you more business in the future!
|
Welcome to on-line drugstore. We will deliver your order to your door by air mail. Time of delivery is 2-4 weeks around the world. Fast Shipping is available. Delivery fee is $7 per any order. No prescription necessary for any medication.
|
|
| Atrovent aerosol 10ml 200 dosis |
 Price: $23.95
|
Category: respiratory system
Price: $23.95
Where made: Germany, Boehringer Ingelheim
 Fast Shipping is available.
Buy
|
Detail info about the product:
Packing: 1aerosol 10ml, 200 dosis
Pharmacology:
Ipratropium, a quaternary ammonium derivative of atropine, is an anticholinergic drug having bronchodilator properties. On inhalation the onset of action is noted within 5 to 15 minutes with a peak response between 1 and 2 hours, lasting about 2 additional hours with subsequent decline. An inhaled dose of 40 µg induces bronchodilator effect lasting for some 6 hours.
Significant alterations on airway mucous secretion, mucociliary clearance of sputum, or gas exchange have not been observed. Systemic absorption of ipratropium is poor and the blood levels reached are very low. Metabolic studies with ipratropium in healthy volunteers show an average elimination half-life of 3.5 hours (range 1.5 to 4). The drug is transformed to some 8 metabolites with little or no anticholinergic activity.
In controlled 90 days studies in patients with bronchospasm associated with chronic obstructive pulmonary disease (chronic bronchitis and emphysema) significant improvements in pulmonary function (FEV 1 and FEF 25Ã75% increases of 15% or more) occurred within 15 minutes, reached a peak in 1 to 2 hours, and persisted for periods of 3 to 4 hours in the majority of patients and up to 6 hours in some patients.
Indications:
As a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Contraindications:
In patients with a history of hypersensitivity to soya lecithin or related food products such as soybean and peanut. It should also not be taken by patients hypersensitive to ipratropium bromide, atropinics or any other aerosol components.
Warnings:
Ipratropium should not be used for the abatement of the acute episodes of bronchospasm where rapid response is required, since the drug has a slower onset of effect than that of an adrenergic b 2-agonist aerosol.
Care should be taken to ensure that ipratropium does not reach the eye. There have been isolated reports of ocular complications (i.e., mydriasis, increased intraocular pressure, glaucoma and eye pain) when aerosolized ipratropium, either alone or in combination with an adrenergic b 2-agonist, has been released into the eyes. Ocular events have occurred when the aerosol was used with the standard mouthpiece or with a spacing device.
Eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema may be signs of acute narrow-angle glaucoma. Should any of these symptoms develop, treatment with miotic drops should be initiated and specialist advice sought immediately. In the event that glaucoma is precipitated or worsened, treatment should include standard measures for this condition.
Immediate hypersensitivity reactions may occur after administration of ipratropium metered dose aerosol, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, oropharyngeal edema and anaphylaxis.
Patients with cystic fibrosis may be more prone to gastrointestinal motility disturbances.
Precautions:
General: To ensure optimal delivery to the bronchial tree, the patient should be properly instructed by the physician or other health professional in the use of the inhaler.
Caution is advised against the release of the aerosol into the eyes. Due care should be taken when a spacing device is employed.
In patients with narrow-angle glaucoma, prostatic hyperplasia, urinary retention or bladder neck obstruction, ipratropium should be used with caution.
If a reduced response to ipratropium becomes apparent, the patient should seek medical advice.
Immediate hypersensitivity reactions may occur after administration of ipratropium metered dose aerosol (see Warnings).
Like other pressurized aerosol formulations, Atrovent contains fluorocarbon propellants trichloromonofluoromethane, dichlorodifluoromethane, 1,2-dichlorotetrafluoroethane. Such propellants may be hazardous if they are deliberately abused. Inhalation of high concentrations of aerosol sprays has brought about toxic cardiovascular effects and even death, especially under conditions of hypoxia. However, evidence attests to the relative safety of aerosols when used properly and with adequate ventilation. The recommended dose should not be exceeded and the patient should be so informed.
Pregnancy:
The safety in pregnancy has not been established. The benefits of using ipratropium when pregnancy is present or suspected must be weighed against the possible hazards caused to the fetus. Studies in rats, mice and rabbits showed no embryotoxic nor teratogenic effects.
Lactation:
No specific studies have been conducted on excretion of this drug in breast milk. Benefits during lactation should therefore be weighed against possible effects on the infant.
Children:
Efficacy and safety in children younger than 12 years have not been established.
Drug Interactions :
In patients receiving other anticholinergic drugs, ipratropium should be used with caution because of possible additive effects.
Xanthine derivatives and b 2-adrenergic agents may enhance the effect of ipratropium.
Anticholinergic side effects such as tachycardia and palpitation, tremor, ocular accomodation disturbances, gastrointestinal motility disturbances and urinary retention are rare and reversible, although the risk of urinary retention may be increased in patients with pre-existing outflow tract obstruction.
Ocular side effects have been reported (see Warnings).
As with other inhaled therapy including bronchodilators, cough, local irritation and in very rare instances exacerbation of symptoms and paradoxical bronchoconstriction has been observed.
Allergic-type reactions such as skin rash, angioedema of the tongue, lips and face, urticaria (including giant urticaria), laryngospasm and anaphylactic reactions have been reported, in most of the patients who had a history of allergy to other drugs and/or foods, including soybean.
Overdose:
Symptoms and Treatment: Doses of ipratropium up to 1.2 mg (60 puffs) have been administered by inhalation without the appearance of serious systemic anticholinergic effects. Minor systemic manifestations of anticholinergic action, including dry mouth, visual accomodation disturbances and increase of heart rate may occur.
Should signs of serious anticholinergic toxicity appear, cholinesterase inhibitors may be considered.
Dosage:
The optimal maintenance dosage must be individually determined. The recommended dosage is 2 metered doses (actuations) (40 µg) 3 or 4 times daily. Some patients may need up to 4 metered doses (actuations) (80 µg) at a time to obtain maximum benefit during early treatment. The maximum daily dose should not exceed 12 metered doses (actuations) (240 µg) and the minimum interval between doses should not be less than 4 hours.
Stability and Storage:
The aerosol canister should be stored at room temperature (15 to 30°C); the contents are stable up to the expiration date stamped on the label. Caution: contents under pressure. Container may explode if heated. Do not place in hot water or near radiators, stoves or other sources of heat. Do not puncture or incinerate container or store at temperatures over 30°C. Keep out of reach of children.
Supplied:
Each metal canister with mouthpiece (oral adaptor) contains: ipratropium bromide 140 or 200 doses. Each valve depression delivers 20 µg. Nonmedicinal ingredients: propellants (difluorodichloromethane, monofluorotrichloromethane, tetrafluorodichloroethane) and soya lecithin. Store between 15 and 30°C.
|
Buy
|
|
|
|
|
English 
